Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cisco who wrote (752)	12/22/1997 12:19:00 AM
From: John Zwiener	Respond to of 1894

CICSO, I typed the last message fast. The insider selling is enough to make me look further into why they are doing it, but I do not think this has anything to do with the OB/GYN article. There were studies before that article that made it clear to me, that cytc probably had something good going. While the OB/GYN article was marginally OK, I interpreted it in light of the other studies, which I understand were part of the FDA submission. Also, biopsy confirmed findings lend a separate confirmation to pap or thinprep findings. I do not know about the adjudication cytologist findings, but it does not make sense to me that there would be such a discrepancy when presumably the original calls were made blinded. Also, remember that the pap was done first and removed cells that otherwise would have been sampled if the thinprep had been done first. In subsequent studies, it is even more clear that the thinprep is clearly better than the pap. The NCI estimates over $3 billion is extra costs do to equivical calls on the pap smears which thinprep may reduce quite a bit. Also, it reduces the need to redo pap smears since there are fewer unsatisfactory tests. The women that tend to get cervical carcinoma are also the ones that are more difficult to get in , in the first place and can be difficult to locate. With the insider selling, I believe that the IPO had 3 million shares, followed by another 1 million. But insiders originally had 9 million shares, of which the sold 1 million on the IPO, leaving them with 8 million shares. I wonder who holds these shares at this time.